{
    "clinical_study": {
        "@rank": "41773", 
        "arm_group": [
            {
                "arm_group_label": "GER", 
                "description": "All patients with a diagnosis of schizophrenia, bipolar disorder or major depressive disorder treated with Seroquel\u00ae or Seroquel\u00ae XR seen by general practitioners and psychiatrists in Germany based upon patient encounters recorded in IMS Disease Analyzer during the calendar period 13 February 2012 - 31 August 2012"
            }, 
            {
                "arm_group_label": "UK", 
                "description": "All patients with a diagnosis of schizophrenia, bipolar disorder or major depressive disorder treated with Seroquel\u00ae or Seroquel\u00ae XR seen by general practitioners in the United Kingdom based upon patient encounters recorded in IMS Disease Analyzer  during the calendar period from 11 January 2012 - 31 July 2012"
            }
        ], 
        "brief_summary": {
            "textblock": "A study to evaluate the effectiveness of an update of educational materials with respect to\n      evaluation of monitoring of metabolic parameters"
        }, 
        "brief_title": "EMR Data to Assess Monitoring of Patients Treated With Quetiapine", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Schizophrenia", 
            "Bipolar Disorder", 
            "Major Depressive Disorder"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Bipolar Disorder", 
                "Depressive Disorder", 
                "Depression", 
                "Schizophrenia", 
                "Depressive Disorder, Major"
            ]
        }, 
        "detailed_description": {
            "textblock": "Objective assessment of metabolic monitoring in patients treated with Seroquel\u00ae or Seroquel\u00ae\n      XR/quetiapine fumarate: use of IMS Disease Analyzer to assess physician behaviour in the UK\n      and Germany"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - Electronic medical records of patients with diagnoses of schizophrenia, Bipolar Disorder\n        (BPD) or Major Depressive Disorder (MDD) treated with Seroquel\u00ae or Seroquel\u00aeXR during the\n        calendar periods: 13 Feb - 31 Aug 2012 seen by GP & psychiatrists in Germany & 11 Jan-31\n        July 2012 seen by GPs in the UK\n\n        Exclusion Criteria:\n\n        - Patients with above mentioned diagnoses treated with Seroquel\u00ae or Seroquel\u00ae\n        XR/quetiapine fumarate not having any medical encounters during the time periods: 13 Feb -\n        31 Aug 2012 in Germany & 11 Jan-31 July 2012 by GPs in the UK"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Cross sectional assessment of physician encounters with patients"
            }
        }, 
        "enrollment": {
            "#text": "6153", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01793324", 
            "org_study_id": "D1443C00128"
        }, 
        "intervention_browse": {
            "mesh_term": "Quetiapine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Effectiveness of risk minimization", 
            "Metabolic monitoring", 
            "Seroquel\u00ae or Seroquel\u00ae XR/quetiapine fumarate"
        ], 
        "lastchanged_date": "January 27, 2014", 
        "number_of_groups": "2", 
        "official_title": "Objective Assessment of Metabolic Monitoring in Patients Treated With Seroquel\u00ae or Seroquel\u00ae XR/Quetiapine Fumarate: Use of IMS Disease Analyzer to Assess Physician Behaviour in the UK and Germany", 
        "overall_official": {
            "affiliation": "AZ", 
            "last_name": "Robert S Brody, MPH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Netherlands: Medicines Evaluation Board (MEB)", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Determination whether physicians in the UK and Germany perform monitoring of patients treated with Seroquel\u00ae and Seroquel\u00ae XR including measurement of the following during patient encounters: weight at drug initiation and over the course of treatment.", 
                "safety_issue": "No", 
                "time_frame": "Over 6 months following the distribution of metabolic educational materials in the country"
            }, 
            {
                "measure": "Monitoring of hyperlipidemia during patient encounters.", 
                "safety_issue": "No", 
                "time_frame": "Over 6 months following the distribution of metabolic educational materials in the country"
            }, 
            {
                "measure": "Monitoring for signs and symptoms of hyperglycemia during patient encounters.", 
                "safety_issue": "No", 
                "time_frame": "Over 6 months following the distribution of metabolic educational materials in the country"
            }, 
            {
                "measure": "Monitoring of blood glucose in patients with diabetes; monitoring of patients with risk factors for diabetes for worsening of glycemic control during patient encounters.", 
                "safety_issue": "No", 
                "time_frame": "Over 6 months following the distribution of metabolic educational materials in the country"
            }, 
            {
                "measure": "Counseling patients on healthy eating, exercise and healthy lifestyle improvements during patient encounters.", 
                "safety_issue": "No", 
                "time_frame": "Over 6 months following the distribution of metabolic educational materials in the country"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01793324"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}